Abbott Laboratories: insider trades · United States · SEC (Form 4)

About Abbott Laboratories

Abbott Laboratories (ticker: ABT) is a global healthcare company listed in the United States on the NYSE/NASDAQ and headquartered in Abbott Park, Illinois, United States. Founded in 1888 by Dr. Wallace C. Abbott, the company has evolved from a traditional pharmaceutical business into a diversified healthcare platform with meaningful positions across medical technologies, diagnostics, nutrition and branded generic medicines. For international investors, Abbott is typically viewed as a high-quality large-cap healthcare name with defensive characteristics, recurring revenue streams and a long record of product innovation. Abbott’s business is organized around four main segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals. Medical Devices is now the key growth engine and includes leading franchises in diabetes care, cardiovascular therapies and other intervention-focused technologies. The company’s flagship FreeStyle Libre continuous glucose monitoring system is one of the best-known products in the sector and has helped Abbott build a strong position in diabetes technology. Abbott also sells a broad set of cardiovascular and electrophysiology products, including solutions for structural heart care, rhythm management and minimally invasive procedures. Diagnostics provides laboratory and molecular testing systems, Nutrition covers adult, pediatric and specialty nutrition, and Established Pharmaceuticals sells branded generic medicines in a broad range of international markets. From a competitive standpoint, Abbott holds a strong position in several attractive healthcare niches thanks to its scale, regulatory expertise, global distribution and steady innovation pipeline. Its portfolio benefits from a combination of recurring consumable revenue, installed-base economics and relatively high barriers to entry in areas such as glucose monitoring and advanced cardiovascular devices. This makes Abbott particularly resilient compared with more cyclical industrial or consumer businesses, while still offering above-average growth potential for a mature healthcare company. Geographically, Abbott has a broad global footprint, with meaningful sales in the United States and across international markets. That diversification supports earnings stability, although it also exposes the company to foreign exchange movements and different reimbursement and regulatory regimes. Recent company disclosures point to solid operational momentum: Abbott reported strong 2025 results, with growth led by Medical Devices and its base business, and it issued 2026 guidance reflecting continued expansion. In 2026, Abbott also announced the acquisition of Exact Sciences, which materially strengthens its diagnostics platform and expands its exposure to cancer screening and early detection. Overall, Abbott remains one of the most established healthcare franchises on the market, combining scale, innovation and long-term earnings quality.